II. Preparations
- Tenofovir Disoproxil Fumarate (TDF)
- Original Tenofovir formulation and used in Stribild, Truvada and Complera
- Associated with nephrotoxicity and decreased Bone Mineral Density
- Tenofovir Alafenamide Fumarate (TAF)
- Tenofovir formulation released in 2016 and used in Genvoya, Descovy, Odefsey
- TAF appears to have less adverse Renal Function and Bone Mineral Density effects than the original TDF
- TAF is associated with greater weight gain and dyslipidemia than TDF
III. Mechanism
IV. Adverse Effects
- See nRTI for adverse effects attributed to the class
- Renal dysfunction
- Increased Serum Creatinine
- Proteinuria
- Electrolyte abnormalities
- Acute Renal Failure (1% risk)
- Associated with longer duration of therapy, advanced HIV or pre-existing renal disease
- Gastrointestinal
- Miscellaneous
- Headache
- Hepatitis B flares on withdrawal of medication
V. Dosing
- Dose: 300 mg orally daily
VI. Monitoring
- Obtain Urinalysis every 6 months when on Tenofovir Disoproxil Fumarate
- Obtain baseline Renal Function and Phosphorus, then at 2-8 weeks, and then every 3-6 months
VII. References
Images: Related links to external sites (from Bing)
Related Studies
tenofovir (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TENOFOVIR DISOPROXIL FUMARATE 300 MG TABLET | Generic | $0.52 each |
taf (on 2/22/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
TAFLUPROST 0.0015% EYE DROP | Generic | $4.29 each |
viread (on 2/23/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
VIREAD 300 MG TABLET | Generic | $0.52 each |